Status:
UNKNOWN
Place of 68Ga-PSMA-11 PET-CT in the Therapeutic Decision at the End of the Initial Staging for High Risk Prostate Cancer Patients
Lead Sponsor:
Central Hospital, Nancy, France
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
Several studies have shown a great potential of 68Ga-PSMA PET in high risk prostate cancers patients and a high detection rate than 18F-Choline PET. The primary aim of this study is to evaluate the d...
Eligibility Criteria
Inclusion
- high risk prostate cancer patients with initial tests : CT, bone scintigraphy and 18F-Choline
Exclusion
- contraindication of 68Ga-PSMA PET-CT
Key Trial Info
Start Date :
January 2 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2019
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT03344822
Start Date
January 2 2018
End Date
December 31 2019
Last Update
November 17 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Central hospital Nancy
Nancy, France, 54000